Mesoblast Ltd
MESO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001345099
No open-market purchases or sales by Mesoblast Ltd insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $53.3M in total; no superinvestor holds it.
Other share classesMEOBF
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Mesoblast Ltd insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Mesoblast Ltd, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Obrien James Michael | Chief Financial Officer | – | Jul 9, 2026 | 1 |
| George Gregory | Director, 10% Owner | 8,324,072Indirect | Apr 13, 2026 | 2 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2026 (view filing) | Apr 4-10 | 9 daysLate | George GregoryDirector, 10% Owner | PPurchase | +7.91M | $1.44 | +$11.4M | +1,915.0%8.32M after | 15 lots |
| Apr 10, 2026 (view filing) | Apr 4-10 | 6 daysLate | George GregoryDirector, 10% Owner | PPurchase | +8.31M | $3.15 | +$26.1M | +45,864.0%8.32M after | 15 lots |